Venetoclax plus azacitidine with or without homoharringtonine followed by allogeneic haematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukaemia: A multicentre cohort study

Documenti analoghi

• Venetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study
  di: Elisabetta Petracci, et al.
  Pubblicazione: (2025)
• Venetoclax therapy in chronic lymphocytic leukaemia patients relapsed after allogeneic haematopoietic stem cell transplantation
  di: Francesca Perutelli, et al.
  Pubblicazione: (2025)
• Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax‐based therapy
  di: Guangyang Weng, et al.
  Pubblicazione: (2024)
• Venetoclax‐based non‐intensive combinations for relapsed/refractory acute myeloid leukaemia—Real‐world data from a UK ‐wide programme
  di: Henry Wood, et al.
  Pubblicazione: (2025)
• Acute cholangitis with acute myeloid leukaemia: A case report
  di: Di Cheng, et al.
  Pubblicazione: (2024)